Immunitybio Inc (IBRX)
ImmunityBio Inc (NASDAQ-IBRX) is a Healthcare biotechnology company, and its listed security is common stock on the NASDAQ exchange. The shares represent common equity in the business rather than a separate fund, bond, or depositary receipt. ImmunityBio develops biologic and immune-based medicines, with work centered on therapies and research programs for cancer and infectious diseases. Its activities are tied to the broader biotechnology sector, where companies typically rely on scientific development and regulatory progress. As a NASDAQ-listed common stock, IBRX reflects ownership interest in the company and trades in the public equity market.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IBRX
|
$7.27
|
-9.1% Downside
|
Fair
|
$13
|
62.5% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-9.7x
|
-9.5x
|
58.9x
|
7.85 B
|
9.05 B
|
12.5%
|
37.6%
|
-6.9
|
—
|
35.0%
|
